Dexilant 30-60mg 14 capsules

Dexilant Composition:
active substance: dexlansoprazole;
1 capsule contains 30 mg of dexlansoprazole (granules-LL – 7.5 mg of dexlansoprazole and granules-H – 22.5 mg of dexlansoprazole) or 60 mg of dexlansoprazole (granules-LS – 15 mg of dexlansoprazole and granules-H – 45 mg of dexlansoprazole). excipients: granules-LL: spherical sugar; magnesium carbonate; saccharose; hydroxypropyl cellulose is low substituted; hydroxypropyl cellulose; hypromellose 2910; talc; titanium dioxide (E 171); methacrylate copolymer dispersion; polyethylene glycol 8000; polysorbate 80; colloidal anhydrous silicon dioxide; granules-LS: spherical sugar; magnesium carbonate; saccharose; hydroxypropyl cellulose is low substituted; hydroxypropyl cellulose; hypromellose 2910; talc; titanium dioxide (E 171); methacrylate copolymer dispersion; polyethylene glycol 8000; polysorbate 80; colloidal anhydrous silicon dioxide; granules-H: spherical sugar; magnesium carbonate; saccharose; hydroxypropyl cellulose is low substituted; hydroxypropyl cellulose; hypromellose 2910; talc; titanium dioxide (E 171); methacrylate copolymer (type B); methacrylate copolymer (type A); triethyl citrate; silicon dioxide colloidal anhydrous.

Pharmacotherapeutic group:
Proton pump inhibitors. Code ATX A02B C06.

Indication:
Treatment of all stages of erosive esophagitis in patients aged 12 years and older for a period of up to 8 weeks. Supportive treatment of erosive esophagitis and relief of heartburn in patients 12 years of age and older for up to 6 months in adult patients and 16 weeks in patients 12 to 17 years of age. Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease in patients 12 years of age and older for 4 weeks.

Produced in Italy